olaparib
FDA Expert Panel Recommends Lynparza, Zytiga Combo Only for BRCA1/2-Mutated Prostate Cancer Patients
The ODAC made the recommendation based on data from the PROpel trial, which demonstrated the greatest benefit in patients with BRCA1/2-mutated mCRPC.
AstraZeneca Oncology Rx Sales Grow 19 Percent in Q1 as Execs Lay Out Expansion Plans in Lung Cancer
Premium
By 2030, the firm is planning to develop new treatments that 50 percent of lung cancer patients will be eligible for.
Lynparza, Ceralasertib Combo Trial Provides Clues on Biomarkers of Response in Pediatric Cancer
Premium
In the tumor-agnostic study, pediatric patients with 11q loss and other alterations associated with replication stress benefited from the dual PARP-ATR inhibitor treatment.
NICE Reverses Course, Recommends Lynparza for BRCA1/2-Mutated Breast, Prostate Cancer
NICE previously said Merck and AstraZeneca's PARP inhibitor wasn't cost-effective but has reconsidered after striking a discounted commercial deal with the drugmakers.
Janssen Files for FDA Approval of PARP Inhibitor Combination in Frontline, BRCA-Positive mCRPC
The drugmaker is seeking approval for niraparib in a biomarker-defined patient population, unlike its competitors developing their PARP inhibitors for all comers.